Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project.
暂无分享,去创建一个
Bie M. P. Verbist | S. Hochreiter | A. Bender | Z. Shkedy | G. Klambauer | W. Talloen | H. Göhlmann | L. Vervoort | O. Thas
[1] S. Hochreiter,et al. DEXUS: identifying differential expression in RNA-Seq studies with unknown conditions , 2013, Nucleic acids research.
[2] Katarzyna H. Kaminska,et al. Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding , 2013, Molecular systems biology.
[3] A. Kortenkamp,et al. Seven benzimidazole pesticides combined at sub-threshold levels induce micronuclei in vitro , 2013, Mutagenesis.
[4] T. Iwawaki,et al. Microsomal Triglyceride Transfer Protein Inhibition Induces Endoplasmic Reticulum Stress and Increases Gene Transcription via Ire1α/cJun to Enhance Plasma ALT/AST* , 2013, The Journal of Biological Chemistry.
[5] Janine Ezendam,et al. Applicability of a keratinocyte gene signature to predict skin sensitizing potential. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.
[6] Alexander Levitzki,et al. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. , 2013, Annual review of pharmacology and toxicology.
[7] Julio Saez-Rodriguez,et al. DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data , 2012, Bioinform..
[8] A. Statnikov,et al. Strategic Applications of Gene Expression: From Drug Discovery/Development to Bedside , 2013, The AAPS Journal.
[9] J. Kleinjans,et al. A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. , 2012, Carcinogenesis.
[10] Rescue of Mtp siRNA-induced hepatic steatosis by DGAT2 siRNA silencing[S] , 2012, Journal of Lipid Research.
[11] J. Scannell,et al. Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.
[12] Magnus Klofsten,et al. Decision‐Making in the Pharmaceutical Industry: Analysis of Entrepreneurial Risk and Attitude Using Uncertain Information , 2011 .
[13] Alexander A. Morgan,et al. Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.
[14] Alexander A. Morgan,et al. Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.
[15] S. Bartz,et al. siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids[S] , 2011, Journal of Lipid Research.
[16] J. Arrowsmith. Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.
[17] T. Hata,et al. Pharmacological Characterization of Diethyl-2-({3-dimethylcarbamoyl-4-[(4′-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetyloxymethyl)-2-phenylmalonate (JTT-130), an Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein , 2011, Journal of Pharmacology and Experimental Therapeutics.
[18] Alexander A. Morgan,et al. Supplementary Materials for Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011 .
[19] Roland Eils,et al. Phenocopy – A Strategy to Qualify Chemical Compounds during Hit-to-Lead and/or Lead Optimization , 2010, PloS one.
[20] Adetayo Kasim,et al. Filtering data from high-throughput experiments based on measurement reliability , 2010, Proceedings of the National Academy of Sciences.
[21] R. Tagliaferri,et al. Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.
[22] B. Taylor,et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner , 2010, Proceedings of the National Academy of Sciences.
[23] Ulrich Bodenhofer,et al. FABIA: factor analysis for bicluster acquisition , 2010, Bioinform..
[24] T. Meert,et al. Effects of phosphodiesterase 10 inhibition on striatal cyclic AMP and peripheral physiology in rats. , 2010, Acta neurobiologiae experimentalis.
[25] A. Gazdar,et al. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors , 2009, Oncogene.
[26] Hinrich W. H. Göhlmann,et al. Gene Expression Studies Using Affymetrix Microarrays , 2009, Chapman and Hall / CRC mathematical and computational biology series.
[27] John A. Tallarico,et al. Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds , 2009, Nature Reviews Drug Discovery.
[28] J. Acquaviva,et al. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. , 2009, Biochimica et biophysica acta.
[29] L. Rudel,et al. Microsomal Triglyceride Transfer Protein Enhances Cellular Cholesteryl Esterification by Relieving Product Inhibition* , 2008, Journal of Biological Chemistry.
[30] Shu-Dong Zhang,et al. A simple and robust method for connecting small-molecule drugs using gene-expression signatures , 2008, BMC Bioinformatics.
[31] Hinrich W. H. Göhlmann,et al. I/NI-calls for the exclusion of non-informative genes: a highly effective filtering tool for microarray data , 2007, Bioinform..
[32] T. Skopek,et al. Diagnosis of drug-induced renal tubular toxicity using global gene expression profiles , 2007, Journal of Translational Medicine.
[33] A. Bender,et al. Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.
[34] E. Moler,et al. Development of a Screening Assay for Surrogate Markers of Chk1 Inhibitor-Induced Cell Cycle Release , 2006, Journal of biomolecular screening.
[35] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[36] Véronique Thybaud,et al. SFTG international collaborative study on in vitro micronucleus test II. Using human lymphocytes. , 2006, Mutation research.
[37] Daniel Marzin,et al. SFTG international collaborative study on in vitro micronucleus test I. General conditions and overall conclusions of the study. , 2006, Mutation research.
[38] Keara M. Lane,et al. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. , 2006, Cancer research.
[39] Klaus Obermayer,et al. Support Vector Machines for Dyadic Data , 2006, Neural Computation.
[40] Klaus Obermayer,et al. A new summarization method for affymetrix probe level data , 2006, Bioinform..
[41] D. Bol,et al. Gene expression profiling in the discovery, optimization and development of novel drugs: one universal screening platform. , 2006, Pharmacogenomics.
[42] Van V. Brantner,et al. Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.
[43] D. Bojanic,et al. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. , 2005, Drug discovery today.
[44] Stephan Heyse,et al. From targets to leads: the importance of advanced data analysis for decision support in drug discovery. , 2005, Current opinion in drug discovery & development.
[45] Robert A Jolly,et al. The role of transcriptome analysis in pre-clinical toxicology. , 2005, Current molecular medicine.
[46] Gordon K. Smyth,et al. limma: Linear Models for Microarray Data , 2005 .
[47] Geert Molenberghs,et al. Graphical Exploration of Gene Expression Data: A Comparative Study of Three Multivariate Methods , 2003, Biometrics.
[48] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[49] M. Shiomi,et al. MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. , 2001, European journal of pharmacology.
[50] S. Garrett,et al. Metallothionein isoform 1 and 2 gene expression in the human prostate: Downregulation of MT‐1X in advanced prostate cancer , 2000, The Prostate.
[51] A. Wellstein,et al. Induction of the Angiogenic Modulator Fibroblast Growth Factor-binding Protein by Epidermal Growth Factor Is Mediated through Both MEK/ERK and p38 Signal Transduction Pathways* , 2000, The Journal of Biological Chemistry.
[52] J. Woodburn,et al. The epidermal growth factor receptor and its inhibition in cancer therapy. , 1999, Pharmacology & therapeutics.
[53] Ronald W. Davis,et al. Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.
[54] X. Hua,et al. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis , 1994, Cell.
[55] H. Gylling,et al. Effects of ketoconazole on cholesterol precursors and low density lipoprotein kinetics in hypercholesterolemia. , 1993, Journal of lipid research.
[56] S. Malawista,et al. Microtubule Crystals: A New Biophysical Phenomenon induced by Vinca Alkaloids , 1968, Nature.